FLB Stock Chart & Stats
€0.56
€0.07(9.49%)
At close: 4:00 PM EDT
€0.56
€0.07(9.49%)
Day’s Range― - ―
52-Week Range€0.54 - €1.42
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
€233.39M
Enterprise Value-€127.05
Total Cash (Recent Filing)€476.72M
Total Debt (Recent Filing)€28.09M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 10, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding392,578,800
10 Day Avg. Volume100
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.15
Price to Sales (P/S)5.72
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€71.34M
Bulls Say, Bears Say
Bulls Say
Divestiture Proceeds And M&A FundingDivestiture proceeds of about $350 million provide upfront cash that can be deployed to fund strategic acquisitions and support the company's core M&A strategy.
Path To Adjusted EBITDAManagement's expectation to reach positive adjusted EBITDA by the end of 2026 signals a clear path toward profitability if macro pressures ease.
Restructuring And Cost ReductionsAnnounced restructuring and $40 million of cost actions are expected to improve operating margins and bolster the profit and loss statement.
Bears Say
Academic Funding And Demand WeaknessOngoing weakness in academic funding and soft capital expenditure trends are pressuring instrument demand and core revenue.
Fewer Near-term Catalysts And Limited Deal VisibilityFewer near-term catalysts and limited clarity on the pipeline, timing, structure, and funding of potential acquisitions constrain upside for the stock.
Reduced Growth Outlook From Asset SaleSale of SomaLogic lowers the company's growth outlook and reduces visibility on potential revenue-driving catalysts.
Standard BioTools News
FLB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was €0.54 and its highest was €1.42 in the past 12 months.
What is Standard BioTools’s market cap?
Standard BioTools’s market cap is €233.39M.
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is Nov 10, 2026 which is in 61 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Aug 05, 2026. The company reported -€0.061 earnings per share for the quarter, missing the consensus estimate of -€0.011 by -€0.049.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Overvalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -0.02.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 392,578,800 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -€0.061 in its last earnings report, missing expectations of -€0.011. Following the earnings report the stock price went down -5.674%.
Which hedge fund is a major shareholder of Standard BioTools?
Currently, no hedge funds are holding shares in DE:FLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Standard BioTools Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Standard BioTools
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.